PURPOSE: Benign prostatic hyperplasia and hypogonadism are common disorders in aging men. There is concern that androgen replacement in older men may increase prostate size and symptoms of benign prostatic hyperplasia. We examined whether combining dutasteride, which inhibits testosterone to dihydrotestosterone conversion, with testosterone treatment in older hypogonadal men with benign prostatic hyperplasia reduces androgenic stimulation of the prostate compared to testosterone alone. MATERIALS AND METHODS: We conducted a double-blind, placebo controlled trial of 53 men 51 to 82 years old with symptomatic benign prostatic hyperplasia, prostate volume 30 cc or greater and serum total testosterone less than 280 ng/dl (less than 9.7 nmol/l). Subjects were randomized to daily transdermal 1% T gel plus oral placebo or dutasteride for 6 months. Testosterone dosing was adjusted to a serum testosterone of 500 to 1,000 ng/dl. The primary outcomes were prostate volume measured by magnetic resonance imaging, serum prostate specific antigen and androgen levels. RESULTS: A total of 46 subjects completed all procedures. Serum testosterone increased similarly into the mid-normal range in both groups. Serum dihydrotestosterone increased in the testosterone only but decreased in the testosterone plus dutasteride group. In the testosterone plus dutasteride group prostate volume and prostate specific antigen (mean ± SEM) decreased 12% ± 2.5% and 35% ± 5%, respectively, compared to the testosterone only group in which prostate volume and prostate specific antigen increased 7.5% ± 3.3% and 19% ± 7% (p = 0.03 and p = 0.008), respectively, after 6 months of treatment. Prostate symptom scores improved in both groups. CONCLUSIONS: Combined treatment with testosterone plus dutasteride reduces prostate volume and prostate specific antigen compared to testosterone only. Coadministration of a 5α-reductase inhibitor with testosterone appears to spare the prostate from androgenic stimulation during testosterone replacement in older, hypogonadal men with symptomatic benign prostatic hyperplasia.
RCT Entities:
PURPOSE:Benign prostatic hyperplasia and hypogonadism are common disorders in aging men. There is concern that androgen replacement in older men may increase prostate size and symptoms of benign prostatic hyperplasia. We examined whether combining dutasteride, which inhibits testosterone to dihydrotestosterone conversion, with testosterone treatment in older hypogonadal men with benign prostatic hyperplasia reduces androgenic stimulation of the prostate compared to testosterone alone. MATERIALS AND METHODS: We conducted a double-blind, placebo controlled trial of 53 men 51 to 82 years old with symptomatic benign prostatic hyperplasia, prostate volume 30 cc or greater and serum total testosterone less than 280 ng/dl (less than 9.7 nmol/l). Subjects were randomized to daily transdermal 1% T gel plus oral placebo or dutasteride for 6 months. Testosterone dosing was adjusted to a serum testosterone of 500 to 1,000 ng/dl. The primary outcomes were prostate volume measured by magnetic resonance imaging, serum prostate specific antigen and androgen levels. RESULTS: A total of 46 subjects completed all procedures. Serum testosterone increased similarly into the mid-normal range in both groups. Serum dihydrotestosterone increased in the testosterone only but decreased in the testosterone plus dutasteride group. In the testosterone plus dutasteride group prostate volume and prostate specific antigen (mean ± SEM) decreased 12% ± 2.5% and 35% ± 5%, respectively, compared to the testosterone only group in which prostate volume and prostate specific antigen increased 7.5% ± 3.3% and 19% ± 7% (p = 0.03 and p = 0.008), respectively, after 6 months of treatment. Prostate symptom scores improved in both groups. CONCLUSIONS: Combined treatment with testosterone plus dutasteride reduces prostate volume and prostate specific antigen compared to testosterone only. Coadministration of a 5α-reductase inhibitor with testosterone appears to spare the prostate from androgenic stimulation during testosterone replacement in older, hypogonadal men with symptomatic benign prostatic hyperplasia.
Authors: M Y Roth; S T Page; K Lin; B D Anawalt; A M Matsumoto; C N Snyder; B T Marck; W J Bremner; J K Amory Journal: J Clin Endocrinol Metab Date: 2010-05-19 Impact factor: 5.958
Authors: C G Roehrborn; J D McConnell; M Lieber; S Kaplan; J Geller; G H Malek; R Castellanos; S Coffield; B Saltzman; M Resnick; T J Cook; J Waldstreicher Journal: Urology Date: 1999-03 Impact factor: 2.649
Authors: G Schatzl; C Brössner; S Schmid; W Kugler; M Roehrich; T Treu; A Szalay; B Djavan; C P Schmidbauer; S Söregi; S Madersbacher Journal: Urology Date: 2000-03 Impact factor: 2.649
Authors: Claus G Roehrborn; John D McConnell; Brian Saltzman; Donald Bergner; Todd Gray; Perinchery Narayan; Thomas J Cook; Amy O Johnson-Levonas; Wilson A Quezada; Joanne Waldstreicher Journal: Eur Urol Date: 2002-07 Impact factor: 20.096
Authors: John K Amory; Nelson B Watts; Kirk A Easley; Paul R Sutton; Bradley D Anawalt; Alvin M Matsumoto; William J Bremner; J Lisa Tenover Journal: J Clin Endocrinol Metab Date: 2004-02 Impact factor: 5.958
Authors: Frans Debruyne; Jack Barkin; Peter van Erps; Mario Reis; Teuvo L J Tammela; Claus Roehrborn Journal: Eur Urol Date: 2004-10 Impact factor: 20.096
Authors: Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2003-06-24 Impact factor: 91.245
Authors: Arthi Thirumalai; Lori A Cooper; Katya B Rubinow; John K Amory; Daniel W Lin; Jonathan L Wright; Brett T Marck; Alvin M Matsumoto; Stephanie T Page Journal: J Clin Endocrinol Metab Date: 2016-05-12 Impact factor: 5.958
Authors: Stephen E Borst; Joshua F Yarrow; Christine F Conover; Unyime Nseyo; John R Meuleman; Judyta A Lipinska; Randy W Braith; Darren T Beck; Jeffrey S Martin; Matthew Morrow; Shirley Roessner; Luke A Beggs; Sean C McCoy; Darryl F Cannady; Jonathan J Shuster Journal: Am J Physiol Endocrinol Metab Date: 2013-12-10 Impact factor: 4.310
Authors: Katya B Rubinow; Tomas Vaisar; Chongren Tang; Alvin M Matsumoto; Jay W Heinecke; Stephanie T Page Journal: J Lipid Res Date: 2012-04-13 Impact factor: 5.922